These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 7486908)

  • 1. Sequential, single-dose pharmacokinetic evaluation of meropenem in hospitalized infants and children.
    Blumer JL; Reed MD; Kearns GL; Jacobs RF; Gooch WM; Yogev R; Willims K; Ewing BJ
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1721-5. PubMed ID: 7486908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of meropenem in patients with intra-abdominal infections.
    Bedikian A; Okamoto MP; Nakahiro RK; Farino J; Heseltine PN; Appleman MD; Yellin AE; Berne TV; Gill MA
    Antimicrob Agents Chemother; 1994 Jan; 38(1):151-4. PubMed ID: 8141572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic study of meropenem in healthy beagle dogs receiving intermittent hemodialysis.
    Byun SY; Jeong JW; Choi JH; Lee KP; Youn HY; Maeng HJ; Song KH; Koo TS; Seo KW
    J Vet Pharmacol Ther; 2016 Dec; 39(6):560-565. PubMed ID: 27302674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-dose pharmacokinetics of ceftibuten (SCH 39720) in infants and children.
    Kearns GL; Reed MD; Jacobs RF; Ardite M; Yogev RD; Blumer JL
    Antimicrob Agents Chemother; 1991 Oct; 35(10):2078-84. PubMed ID: 1759830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis.
    Kuti JL; Nightingale CH; Knauft RF; Nicolau DP
    Clin Ther; 2004 Apr; 26(4):493-501. PubMed ID: 15189746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate.
    Bradley JS; Sauberan JB; Ambrose PG; Bhavnani SM; Rasmussen MR; Capparelli EV
    Pediatr Infect Dis J; 2008 Sep; 27(9):794-9. PubMed ID: 18645546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients.
    Kitzes-Cohen R; Farin D; Piva G; De Myttenaere-Bursztein SA
    Int J Antimicrob Agents; 2002 Feb; 19(2):105-10. PubMed ID: 11850162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.
    Krueger WA; Bulitta J; Kinzig-Schippers M; Landersdorfer C; Holzgrabe U; Naber KG; Drusano GL; Sörgel F
    Antimicrob Agents Chemother; 2005 May; 49(5):1881-9. PubMed ID: 15855510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetics of meropenem in infants and children: a population analysis.
    Parker EM; Hutchison M; Blumer JL
    J Antimicrob Chemother; 1995 Jul; 36 Suppl A():63-71. PubMed ID: 8543500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of meropenem in the treatment of serious infections in children: review of the current literature.
    Arrieta A
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S207-12. PubMed ID: 9126695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetics and Target Attainment of Meropenem in Plasma and Tissue of Morbidly Obese Patients after Laparoscopic Intraperitoneal Surgery.
    Wittau M; Scheele J; Kurlbaum M; Brockschmidt C; Wolf AM; Hemper E; Henne-Bruns D; Bulitta JB
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6241-7. PubMed ID: 26248353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin.
    Dreetz M; Hamacher J; Eller J; Borner K; Koeppe P; Schaberg T; Lode H
    Antimicrob Agents Chemother; 1996 Jan; 40(1):105-9. PubMed ID: 8787889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem.
    Conte JE; Golden JA; Kelley MG; Zurlinden E
    Int J Antimicrob Agents; 2005 Dec; 26(6):449-56. PubMed ID: 16280244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections.
    Smith PB; Cohen-Wolkowiez M; Castro LM; Poindexter B; Bidegain M; Weitkamp JH; Schelonka RL; Ward RM; Wade K; Valencia G; Burchfield D; Arrieta A; Bhatt-Mehta V; Walsh M; Kantak A; Rasmussen M; Sullivan JE; Finer N; Brozanski BS; Sanchez P; van den Anker J; Blumer J; Kearns GL; Capparelli EV; Anand R; Benjamin DK;
    Pediatr Infect Dis J; 2011 Oct; 30(10):844-9. PubMed ID: 21829139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration.
    Giles LJ; Jennings AC; Thomson AH; Creed G; Beale RJ; McLuckie A
    Crit Care Med; 2000 Mar; 28(3):632-7. PubMed ID: 10752806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of meropenem in patients with liver disease.
    Thyrum PT; Yeh C; Birmingham B; Lasseter K
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S184-90. PubMed ID: 9126692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of meropenem administered as a prolonged infusion in children with cystic fibrosis.
    Pettit RS; Neu N; Cies JJ; Lapin C; Muhlebach MS; Novak KJ; Nguyen ST; Saiman L; Nicolau DP; Kuti JL
    J Antimicrob Chemother; 2016 Jan; 71(1):189-95. PubMed ID: 26416780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration.
    Thalhammer F; Schenk P; Burgmann H; El Menyawi I; Hollenstein UM; Rosenkranz AR; Sunder-Plassmann G; Breyer S; Ratheiser K
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2417-20. PubMed ID: 9736573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections.
    Pai MP; Cojutti P; Pea F
    Clin Pharmacokinet; 2015 Sep; 54(9):933-41. PubMed ID: 25850987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic profile of meropenem, administered at 500 milligrams every 8 hours, in plasma and cantharidin-induced skin blister fluid.
    Maglio D; Teng R; Thyrum PT; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2003 May; 47(5):1771-3. PubMed ID: 12709358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.